Pandemic preparedness
Our R&D portfolio for pandemic preparedness
Pandemic preparedness
Our R&D portfolio for pandemic preparedness
What we are doing for pandemic preparedness
In the complex field of drug discovery and development for diseases of pandemic potential, our teams and partners are united by a common goal: placing on humanity’s shelf a collection of potential broad-spectrum antiviral drugs that will be ready for clinical evaluation and scale-up manufacturing to confront new pandemics, and which could be developed quickly into affordable, globally accessible treatments.
We are also advocating for the policies and commitments needed to ensure all people have access to the life-saving medical tools they need. In policy fora and international decision-making bodies such as the World Health Assembly, we speak out for change that we know from our own experience can help shift the scales in the next pandemic.
What we have achieved
We engaged in collaborative drug discovery partnerships to develop affordable, effective new potential treatments for viruses of pandemic concern. One of these open science partnerships led to the discovery and the development of a promising broad-spectrum antiviral with potent activity against coronaviruses.
Free access to 400 diverse chemical compounds. Launched by MMV and DNDi in 2019, this project aims to accelerate drug discovery by providing researchers with free drug-like molecules selected by disease experts for screening against infectious and neglected diseases.
Open-science search for an affordable, globally accessible COVID-19 antiviral. 150 scientists partnered to identify new molecules that could block SARS-CoV-2 infection. A pre-clinical candidate built on the scaffold they discovered and optimized is now being further developed by researchers from the AViDD ASAP consortium.
A multi-country trials focusing on mild and moderate cases of COVID-19. Conducted across 29 clinical trial sites in 13 African countries and Brazil by 27 medical research organizations, the ANTICOV study tested treatments that could reduce the risk of hospitalization.
Open science against the world’s most dangerous viruses. This partnership between DNDi and the German Center for Infection Research (DZIF) is screening a selection of nucleoside drugs for the broadest possible antiviral activity against families of viruses presenting the greatest epidemic and pandemic threats.
Building capacity, uniting expertise
Research platforms and consortiums that bring together researchers and strengthen research capacities in low- and middle-income countries are central to our virtual R&D model.
Partnering for patients
Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in nearly 50 countries.
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
